Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALT Altimmune, Inc.

Closed 04-28 16:00:00 EDT

2.74

-0.06

-2.14%

盘后2.78

+0.04+1.46%

19:56 EDT

High2.85	Low2.72	Vol4.87M
Open2.78	D1 Closing2.80	Amplitude4.64%
Mkt Cap531.56M	Tradable Cap509.64M	Total Shares194.00M
T/O13.48M	T/O Rate2.62%	Tradable Shares186.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALT","market":"US","secType":"STK","nameCN":"Altimmune, Inc.","latestPrice":2.74,"timestamp":1777406400000,"preClose":2.8,"halted":0,"volume":4870640,"hourTrading":{"tag":"盘后","latestPrice":2.78,"preClose":2.74,"latestTime":"19:56 EDT","volume":49823,"amount":137638.3244,"timestamp":1777420571535,"change":0.04,"changeRate":0.014599,"amplitude":0.027883},"delay":0,"changeRate":-0.02142857142857129,"floatShares":186000000,"shares":194000000,"eps":-0.999873,"marketStatus":"Closed","change":-0.06,"latestTime":"04-28 16:00:00 EDT","open":2.78,"high":2.85,"low":2.72,"amount":13480015.897288,"amplitude":0.046429,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.999873,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777449600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.8,"preHourTrading":{"tag":"盘前","latestPrice":2.78,"preClose":2.8,"latestTime":"09:28 EDT","volume":39310,"amount":109793.06586,"timestamp":1777382880129,"change":-0.02,"changeRate":-0.007143,"amplitude":0.032143},"postHourTrading":{"tag":"盘后","latestPrice":2.78,"preClose":2.74,"latestTime":"19:56 EDT","volume":49823,"amount":137638.3244,"timestamp":1777420571535,"change":0.04,"changeRate":0.014599,"amplitude":0.027883},"volumeRatio":0.424888,"impliedVol":0.9109,"impliedVolPercentile":0.3506},"requestUrl":"/m/hq/s/ALT/tweets","defaultTab":"tweets","newsList":[{"id":"2630398277","title":"Altimmune closes USD 225 million follow-on stock offering with warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2630398277","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630398277?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:03","pubTimestamp":1777287838,"startTime":"0","endTime":"0","summary":"Altimmune closed an underwritten public offering raising gross proceeds of about USD 225 million.Offering included 64,250,000 common shares with 64,250,000 accompanying common stock warrants at USD 3 per share-warrant package.Investors could instead buy pre-funded warrants for up to 10,750,000 shares with accompanying common stock warrants at USD 2.999 per package.Accompanying common stock warrants are immediately exercisable, expiring on earlier of fifth anniversary or 45 days following public announcement of a successful Phase 3 MASH data readout.Proceeds are expected to fund pemvidutide Phase 3 MASH trial, supporting operations through anticipated 52-week data readout.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL74XD98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00BN0W2V16.EUR","ALT","BK4599","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2W23.USD","SG9999014013.SGD","BK4139","LU1878469433.USD","IE00BKPKM429.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630977398","title":"Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2630977398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630977398?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUARVFFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","BK4139","ALT","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630911398","title":"Altimmune Inc: Financing Funds Operations Through Anticipated Phase 3 Mash 52-Week Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2630911398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630911398?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUARVFFJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","BK4599","ALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630153398","title":"Altimmune Inc: Intends to Use Net Proceeds to Fund Its Upcoming Phase 3 Trial in Mash,  Expects to Initiate Its Phase 3 Trial in Mash in H2","url":"https://stock-news.laohu8.com/highlight/detail?id=2630153398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630153398?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUARVFFJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","BK4599","ALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630382248","title":"Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630382248","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630382248?lang=en_us&edition=fundamental","pubTime":"2026-04-26 19:00","pubTimestamp":1777201200,"startTime":"0","endTime":"0","summary":"- Participants achievingHBsAg loss with pegylated interferon alfa  ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. These findings indicate durable posttreatment immunological control, supporting the potential for safe nucleoside reverse transcriptase inhibitor  discontinuation in regimens combining PEG-IFNα with novel therapeutic modalities.Data from the two studies were pooled to assess the incidence, magnitude and clinical relevance of HBsAg rebound following EOT in participants treated with PEGIFNα alone or in combination with elebsiran or BRII179. Across studies, participants demonstrated favorable offtreatment clinical outcomes. All HBsAg rebounds remained below 100 IU/mL with most rebounds remaining below 10 IU/mL. HBV DNA rebound was infrequent and not associated with clinically meaningful alanine aminotransferase  elevat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/brii-bio-presents-cross-study-analysis-of-post-treatment-hbsag-rebound-at-apasl-2026-302752618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","BK4139","LU1878469433.USD","ALT","EOT","BK4599","POST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629223811","title":"Altimmune upgraded to Neutral from Sell at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2629223811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629223811?lang=en_us&edition=fundamental","pubTime":"2026-04-24 17:16","pubTimestamp":1777022173,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Corinne Johnson upgraded Altimmune (ALT) to Neutral from Sell with a price target of $2.50, up from $1. The company’s financi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/altimmune-upgraded-to-neutral-from-sell-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/altimmune-upgraded-to-neutral-from-sell-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4516","LU2471134952.CNY","LU2265009873.SGD","LU2471134879.HKD","LU0345770993.USD","LU1868837300.USD","LU1894683348.USD","LU0106831901.USD","LU1668664300.SGD","LU0096364046.USD","LU1894683264.USD","BK4533","IE00B19Z3B42.SGD","IE00BFXG1179.USD","IE00BSNM7G36.USD","LU2237443465.HKD","BK4585","LU2237438978.USD","BK4504","LU2750360997.AUD","BK4550","IE0004086264.USD","BK4127","BK4588","BK4552","LU0251131958.USD","LU0061475181.USD","LU0742534661.SGD","ALT","LU2237443978.SGD","IE00B19Z3581.USD","IE0004091025.USD","GSX","IE0034235188.USD","LU0345770308.USD","LU2237443622.USD","LU1868836757.USD","LU0048573561.USD","BK4139","IE0002270589.USD","LU1868836591.USD","LU2471134796.USD","LU2750360641.GBP","LU1868837136.USD","LU2237443549.SGD","LU1804176565.USD","LU1791807156.HKD","LU1878469433.USD","LU1868836914.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629545438","title":"BUZZ-U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2629545438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629545438?lang=en_us&edition=fundamental","pubTime":"2026-04-24 01:44","pubTimestamp":1776966278,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, United Rentals, cannabis stocks Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Cal","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL6N4160QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRCX","ROP","TXN","LULG","NEE","ALT","HAS","INTU","NXPI","REGN","LULU","EFOR","AALG","AXP","FCX","APLD","HON","QS","TMO","APLZ","CRSH","ELMT","TSLA","07766","AAL","PCG","MCHP","IBM","RNA","ON","HLX","KREF","LMT","KDP","LUCD","CSX","ADBE","MBLY","SIRI","PSKY","ADI","CRWD","NFLX","CMCSA","MSFT","INTC","WST","NOW","HELE","ASGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629383839","title":"Altimmune Shares Drop After $225 Million Offering Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2629383839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629383839?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:00","pubTimestamp":1776945600,"startTime":"0","endTime":"0","summary":"Altimmune shares dropped after the biopharmaceutical company priced an underwritten public offering consisting of 64.3 million shares and accompanying warrants to buy 64.3 million shares.Shares were 16% lower, at $2.93, in premarket trading.The Gaithersburg, Md., company said the stock and pre-funded warrants are being sold in combination with an accompanying stock warrant to buy one share of stock or pre-funded warrant sold.The accompanying common stock warrant has an exercise price of $3 a share and is immediately exercisable from the date of issuance, the company said.The combined offering price of each share and accompany common stock warrant is $3, it added.Altimmune said it intends to use the proceeds from this offering to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis, as well as for working capital and general corporate purposes.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4139","BK4599","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629078730","title":"ALT Resources Advances Tartana Reverse Takeover and Secures £208,750 Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2629078730","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629078730?lang=en_us&edition=fundamental","pubTime":"2026-04-23 14:12","pubTimestamp":1776924741,"startTime":"0","endTime":"0","summary":"ACP Energy PLC ( ($GB:ALTR) ) just unveiled an announcement. ALT Resources PLC has reported progress on its proposed acquisition of Tartana Mineral...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alt-resources-advances-tartana-reverse-takeover-and-secures-208750-funding?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alt-resources-advances-tartana-reverse-takeover-and-secures-208750-funding?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4599","ALT","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629003001","title":"Altimmune prices oversubscribed USD 225 million public offering with warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2629003001","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629003001?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:25","pubTimestamp":1776914719,"startTime":"0","endTime":"0","summary":"Altimmune priced an underwritten public offering expected to raise about USD 225 million in gross proceeds.Deal includes 64,250,000 common shares sold with accompanying common stock warrants at a combined price of USD 3 per share.Offering also includes up to 10,750,000 pre-funded warrants with accompanying common stock warrants at a combined price of USD 2.999.Accompanying common stock warrants carry an exercise price of USD 3 per share with expiry tied to a Phase 3 pemvidutide MASH data readout or five years.Net proceeds earmarked to fund upcoming Phase 3 trial in MASH, working capital, general corporate purposes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL3vl7hz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","ALT","BK4588","SG9999014021.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU1878469433.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4599","SG9999014013.SGD","BK4585","BK4139","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU0314104364.USD","LU2210150020.SGD","LU2210149790.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629003076","title":"Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2629003076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629003076?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:25","pubTimestamp":1776914700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nTUA20CY2L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4139","LU1878469433.USD","ALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629765510","title":"BRIEF-Altimmune Announces Proposed Underwritten Public Offering Of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2629765510","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629765510?lang=en_us&edition=fundamental","pubTime":"2026-04-23 06:02","pubTimestamp":1776895356,"startTime":"0","endTime":"0","summary":"BRIEF-Altimmune Announces Proposed Underwritten Public Offering Of SecuritiesApril 22 (Reuters) - Altimmune Inc ALT.O:ALTIMMUNE ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF SECURITIESALTIMMUNE I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA3FQ96N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1878469433.USD","ALT","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629507869","title":"Altimmune launches underwritten public offering with common stock, warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2629507869","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629507869?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:30","pubTimestamp":1776889848,"startTime":"0","endTime":"0","summary":"Altimmune launched an underwritten public offering of common stock with accompanying common stock warrants.Some investors can buy pre-funded warrants in lieu of common stock, paired with common stock warrants.Net proceeds are earmarked for upcoming Phase 3 MASH trial funding.Remaining proceeds will support working capital, general corporate purposes.Leerink Partners, Barclays will run books; Titan Partners will act as co-bookrunner.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL5ZjZCp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BN0W2W23.USD","SG9999014021.USD","LU2646069778.SGD","LU1023061713.HKD","BK4588","LU0964806797.USD","LU0345777659.USD","LU0997586606.USD","LU0314104364.USD","LU1023061473.USD","LU1064927863.SGD","LU1035777561.USD","BARC.UK","BK5152","LU0048578792.EUR","NDAQ","LU0047473722.SGD","ALT","LU2210149790.SGD","LU1078025761.USD","LU0345770308.USD","LU1668664300.SGD","MNSH","LU0047473722.EUR","IE00B3QW5Z07.USD","BK4585","BK4112","IE00BGHQF748.EUR","BK4139","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BKPKM429.USD","BK4207","LU0106831901.USD","LU0171281750.USD","LU0987226296.USD","LU1878469433.USD","BK4599","IE00BN0W2V16.EUR","LU0345770993.USD","LU0550127509.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","LU0345777147.USD","LU0161305163.EUR","LU1791807156.HKD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629214020","title":"Altimmune Announces Proposed Underwritten Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2629214020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629214020?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:19","pubTimestamp":1776889181,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA3FQ96N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","ALT","BK4139","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629020296","title":"Altimmune Inc - Net Proceeds to Fund Phase 3 Mash Trial and General Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2629020296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629020296?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:19","pubTimestamp":1776889181,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA3FQ96N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","BK4599","BK4139","ALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629043131","title":"TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629043131","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629043131?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:30","pubTimestamp":1776857400,"startTime":"0","endTime":"0","summary":"NEW YORK, April  22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278846/8790/en/TG-Therapeutics-Announces-Data-Presentations-for-BRIUMVI-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2026-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TG","BK4127","IE00BZ1G4Q59.USD","CNS","LU0106831901.USD","LU0158827781.USD","IE00BKVL7J92.USD","LU1162221912.USD","LU0098860793.USD","LU1732800096.USD","LU0234570918.USD","LU0882574139.USD","LU1989772923.USD","BK4516","BK4090","LU0314104364.USD","LU1791710582.SGD","LU1548497426.USD","LU2089284900.SGD","LU2111349929.HKD","BK4585","LU1244550494.USD","BK4581","LU1791710400.SGD","LU1878469433.USD","LU1244550221.USD","ALT","PML","LU1732799900.SGD","LU2133065610.SGD","BK4599","TGTX","LU0912757837.SGD","LU0795875086.SGD","LU2347655156.SGD","BK4135","LU2089283258.USD","LU0267386448.USD","LU1720051108.HKD","AFG","BK4139","LU0557290698.USD","LU1074936037.SGD","BK4504","BK4588","LU2271345857.HKD","LU0006306889.USD","LU2023251221.USD","BK4117","LU0528227936.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628991857","title":"KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2628991857","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628991857?lang=en_us&edition=fundamental","pubTime":"2026-04-20 06:00","pubTimestamp":1776636000,"startTime":"0","endTime":"0","summary":"KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma  OS benefit observed across key subgroups, including patients with high","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/19/3276674/0/en/KIMMTRAK-doubles-the-likelihood-of-being-alive-at-five-years-for-first-line-HLA-A-02-01-patients-with-metastatic-uveal-melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRS","LU0963586101.USD","ALT","IE0031619046.USD","IE00B66KJ199.SGD","LU2065731478.USD","BK4187","BK4006","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4599","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628124125","title":"Altimmune shareholders approved increase in authorized common shares to 400 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2628124125","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628124125?lang=en_us&edition=fundamental","pubTime":"2026-04-17 05:08","pubTimestamp":1776373695,"startTime":"0","endTime":"0","summary":"Altimmune held its annual shareholder meeting on April 16, 2026.Shareholders backed an amendment to increase authorized common shares to 400,000,000 from 200,000,000.Holders endorsed an amendment to 2019 employee stock purchase plan, lifting shares reserved to 1,108,827 from 403,500.Shareholders authorized adjournment of meeting to allow additional proxy solicitation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL244gS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4599","ALT","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627410294","title":"Press Release: Harrow Announces the Issuance of J-Code for IOPIDINE(R) 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627410294","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627410294?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:00","pubTimestamp":1776337200,"startTime":"0","endTime":"0","summary":"NASHVILLE, Tenn., April 16, 2026  -- Harrow , a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE 1%  has been assigned a permanent J-Code  by the Centers for Medicare & Medicaid Services . Effective July 1, 2026, IOPIDINE 1% will be reimbursed when administered in the in-office setting.J-Codes are CMS billing designations that allow physicians to be reimbursed directly for drugs administered in their offices. The assignment of a permanent J-Code removes a longstanding practical barrier to routine use of IOPIDINE 1% for office-based procedures, making it administratively and economically feasible for physicians to incorporate IOPIDINE 1% into standard glaucoma and ophthalmic laser procedure workflows.\"This is ultimately about removing friction--for physicians and for patients,\" said Dr. Jason Bacharach, MD. \"As a glaucoma specialist, having a reimbursed, in-office option means I can treat patients in real time as I am counseling","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLT","LU0949170772.SGD","LU0545039389.USD","BK4007","LU0553294199.USD","LU1878469433.USD","BK4139","LU1894683348.USD","BK4599","LU0738911758.USD","BK4588","LU1894683264.USD","R","BK4232","CMS","LU2637428348.USD","BK4022","LU2346227817.USD","BK4208","HROW","ALT","LU0661504455.SGD","BK4557","LU1003077747.HKD","LU2500361329.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625705985","title":"Altimmune Insider Makes Bold New Share Grab","url":"https://stock-news.laohu8.com/highlight/detail?id=2625705985","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625705985?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:02","pubTimestamp":1775527375,"startTime":"0","endTime":"0","summary":"New insider activity at Altimmune ( ($ALT) ) has taken place on April 6, 2026. Altimmune has seen insider confidence grow as Director John Gill pur...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/altimmune-insider-makes-bold-new-share-grab-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/altimmune-insider-makes-bold-new-share-grab-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2362541273.HKD",".IXIC","LU0979878070.USD","LU2125910500.SGD","BK4122","SG9999013478.USD","LU2362540622.SGD","BK4022","SG9999013460.SGD","SG9999002679.SGD","LU1242518857.USD","SG9999002620.SGD","LU1839390173.USD","LU0210637038.USD","SG9999002604.SGD","ALT","LU2045819591.USD","SG9999002406.SGD","SGXZ58947870.SGD","BK4230","SG9999006266.SGD","SG9999013486.USD","LU2362541513.USD","SG9999001135.SGD","SG9999002414.USD","LU1242518931.SGD","LU0532188223.SGD","LU0441851309.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.altimmune.com","stockEarnings":[{"period":"1week","weight":-0.2135},{"period":"1month","weight":-0.0728},{"period":"3month","weight":-0.5469},{"period":"6month","weight":-0.3},{"period":"1year","weight":-0.4477},{"period":"ytd","weight":-0.2244}],"compareEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1279},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2988},{"period":"ytd","weight":0.0488}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.421053,"avgChangeRate":0.021325},{"month":2,"riseRate":0.368421,"avgChangeRate":-0.012068},{"month":3,"riseRate":0.368421,"avgChangeRate":-0.06468},{"month":4,"riseRate":0.368421,"avgChangeRate":-0.051808},{"month":5,"riseRate":0.5,"avgChangeRate":0.064208},{"month":6,"riseRate":0.388889,"avgChangeRate":-0.000157},{"month":7,"riseRate":0.388889,"avgChangeRate":0.041853},{"month":8,"riseRate":0.444444,"avgChangeRate":0.10411},{"month":9,"riseRate":0.210526,"avgChangeRate":-0.115822},{"month":10,"riseRate":0.263158,"avgChangeRate":0.032599},{"month":11,"riseRate":0.421053,"avgChangeRate":-0.007448},{"month":12,"riseRate":0.526316,"avgChangeRate":0.184275}],"exchange":"NASDAQ","name":"Altimmune, Inc.","nameEN":"Altimmune, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Altimmune, Inc.,ALT,Altimmune, Inc.股票,Altimmune, Inc.股票老虎,Altimmune, Inc.股票老虎国际,Altimmune, Inc.行情,Altimmune, Inc.股票行情,Altimmune, Inc.股价,Altimmune, Inc.股市,Altimmune, Inc.股票价格,Altimmune, Inc.股票交易,Altimmune, Inc.股票购买,Altimmune, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}